Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
13F holders, Q2 2026 (June 30)12holders −2
1new positions
3sold out
$0.97avg. 13F price*
At the end of Q2 2026, 12 institutions reported holding Biomarin Pharmaceutical (bmrn 1.25 05/15/27) in their 13F filings, down 2 from Q1 2026. 1 opened new positions and 3 sold out. The largest holders were State of Wisconsin Investment Board ($3.9M), Focus Partners Wealth ($3.1M) and Jupiter Topco LLC ($2.2M).
- Company
- Biomarin Pharmaceutical (bmrn 1.25 05/15/27)
- CUSIP
- 09061GAK7
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $390K |
| Exits | 3 | $2.8M |
All 13F filers, Q1 2026 → Q2 2026: 1,400,000 shares bought and 3,092,225 shares sold, net −1,692,225 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 12 holders
| State of Wisconsin Investment Board | 0.01% | Add +33.3% | 4,000,000 | $3.9M |
| Focus Partners Wealth | 0.00% | Reduce -4.2% | 3,208,000 | $3.1M |
| Jupiter Topco LLC | 0.00% | — | 2,300,000 | $2.2M |
| TD Asset Management Inc | 0.00% | New | 400,000 | $390K |
| Sei Investments Co. | 0.00% | No change | 371,000 | $361K |
| Oppenheimer Asset Management Inc. | 0.00% | Reduce -1.7% | 173,000 | $168K |
| Stephens Inc. | 0.00% | No change | 54,000 | $52K |
| Mariner, LLC | 0.00% | No change | 42,000 | $41K |
| &partners | 0.00% | No change | 18,000 | $17K |
| HB Wealth Management, LLC | 0.00% | No change | 11,000 | $11K |
| DAVENPORT & Co LLC | 0.00% | No change | 10,000 | $10K |
| Cetera Investment Advisers | 0.00% | No change | 10,000 | $10K |
"% of holder's portfolio" is BIOMARIN PHARMACEUTICAL (BMRN 1.25 05/15/27)'s weight in each manager's 13F, not the share of Biomarin Pharmaceutical (bmrn 1.25 05/15/27) the manager owns.